A253840 Share Price Performance
₩7,050.00
-1520.00 (-17.74%)
Price ₩7,050.00
Share Price₩7,050.00
A253840 Community Narratives
There are no narratives available yet.
Recent A253840 News & Updates
No updates
Sugentech Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -938.98
- Gross Margin
- -4.31%
- Net Profit Margin
- -143.20%
- Debt/Equity Ratio
- 5.0%
Sugentech Inc. Competitors
About A253840
- Founded
- 2011
- Employees
- 144
- CEO
- WebsiteView website
Sugentech Inc. develops and sells in-vitro diagnostic systems and products based on biotechnology, information technology, and nanotechnology in South Korea and internationally. The company offers lab tests, including systems and test items; and COVID-19 tests. It also provides point of care testing analyzers and test items for testing of influenza A/B, antibody test, COVID-19 and flu, SARS-CoV-2, HbA1c, beta-hcg, YSH, T3/T4, and CRP; and digital health and home tests, including mobile health, ovulation, and pregnancy products. The company was formerly known as Accugen Healthcare, Inc. and changed its name to Sugentech Inc. in October 2013. Sugentech Inc. was founded in 2011 and is headquartered in Daejeon, South Korea.
South Korean Market Performance
- 7 Days: -1.1%
- 3 Months: 22.2%
- 1 Year: 23.5%
- Year to Date: 30.6%
Over the last 7 days, the market has dropped 1.1%, driven by a loss of 5.7% in the Materials sector. As for the longer term, the market has actually risen by 24% in the last year. As for the next few years, earnings are expected to grow by 22% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading